Feb 08th 2013 - Edison Investment Research today published a report on quickview entitled "An Array Of Opportunities". In summary, the report says:
Multiple potential catalysts in 2013 could add significant value to Array’s currently fair EV of $430m. Array’s extensive oncology pipeline will reach a key milestone in 2013 when its first candidate enters Phase III studies – Novartis will initiate a pivotal trial of its licensed MEK inhibitor (MEK162) for NRAS melanoma in April 2013. AstraZeneca is also expected to finally make a Phase III decision on its licensed MEK inhibitor (selumetinib) in H213. Array’s own drug candidates, ARRY-520 and ARRY-614, could also enter pivotal trials by the end of 2013, pending additional data from ongoing studies. New partners may be secured for Phase II assets in the fields of pain or asthma.
Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »